What is HC Wainwright’s Estimate for Genelux Q1 Earnings?

Genelux Corporation (NASDAQ:GNLX) – Equities researchers at HC Wainwright issued their Q1 2026 earnings estimates for shares of Genelux in a research note issued on Thursday, November 6th. HC Wainwright analyst E. Bodnar expects that the company will post earnings of ($0.26) per share for the quarter. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q2 2026 earnings at ($0.27) EPS, Q3 2026 earnings at ($0.30) EPS and Q4 2026 earnings at ($0.35) EPS.

Genelux (NASDAQ:GNLX) last issued its earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.02.

Several other research firms have also commented on GNLX. Maxim Group set a $20.00 target price on Genelux in a report on Tuesday, October 21st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Genelux from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Loop Capital set a $16.00 target price on shares of Genelux in a research note on Tuesday, October 21st. Finally, Lake Street Capital assumed coverage on Genelux in a research note on Tuesday, October 21st. They issued a “buy” rating and a $16.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Genelux has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Genelux Trading Up 3.3%

Shares of NASDAQ GNLX traded up $0.18 during trading on Friday, reaching $5.48. 102,673 shares of the company traded hands, compared to its average volume of 188,805. The stock has a market cap of $206.79 million, a P/E ratio of -6.22 and a beta of -0.09. The firm’s fifty day simple moving average is $5.13 and its 200 day simple moving average is $3.75. Genelux has a 12-month low of $1.99 and a 12-month high of $8.53.

Hedge Funds Weigh In On Genelux

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Woodward Diversified Capital LLC boosted its stake in shares of Genelux by 3.7% in the third quarter. Woodward Diversified Capital LLC now owns 1,844,099 shares of the company’s stock worth $7,745,000 after acquiring an additional 65,813 shares during the last quarter. 5T Wealth LLC boosted its holdings in shares of Genelux by 33.9% during the 3rd quarter. 5T Wealth LLC now owns 24,101 shares of the company’s stock worth $101,000 after purchasing an additional 6,100 shares during the last quarter. LifeSteps Financial Inc. increased its holdings in shares of Genelux by 8.2% in the third quarter. LifeSteps Financial Inc. now owns 105,171 shares of the company’s stock valued at $442,000 after purchasing an additional 7,952 shares during the last quarter. Flputnam Investment Management Co. lifted its position in Genelux by 708.1% during the third quarter. Flputnam Investment Management Co. now owns 300,290 shares of the company’s stock worth $1,261,000 after buying an additional 263,131 shares in the last quarter. Finally, Osaic Holdings Inc. boosted its stake in Genelux by 1,911.4% during the second quarter. Osaic Holdings Inc. now owns 105,016 shares of the company’s stock worth $301,000 after buying an additional 99,795 shares during the last quarter. Hedge funds and other institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.